期刊
BEST PRACTICE & RESEARCH CLINICAL ENDOCRINOLOGY & METABOLISM
卷 28, 期 6, 页码 809-834出版社
ELSEVIER SCI LTD
DOI: 10.1016/j.beem.2014.09.003
关键词
osteoporosis; treatment; efficacy; safety
资金
- Servier
- Novartis
- Negma
- Lilly
- Wyeth
- Amgen
- GlaxoSmithKline
- Roche
- Merckle
- Nycomed-Takeda
- NPS
- IBSA-Genevrier
- Theramex
- UCB
- Asahi Kasei
- Endocyte
- Merck Sharp and Dohme
- Rottapharm
- IBSA
- Genevrier
- Teijin
- Teva
- Analis
- Nycomed
- NovoNordisk
- Ebewee Pharma
- Zodiac
- Danone
- Will Pharma
- Bristol Myers Squibb
- Merck Sharp Dohme
- Pfizer
- Organon
- Therabel
- Boehringer
- Chiltern
- Galapagos
- Bayer
- SMB
- Nutraveris
During the past 2 decades, many interventions were proven effective in the management of postmenopausal osteoporosis. The objective of an anti-osteoporosis treatment is to reduce fracture rates, ideally at all skeletal sites (i.e. spine, hip, and other non-spine). The armamentarium against osteoporosis includes anti-resorptive agents (i.e. bisphosphonates, selective estrogen receptor modulators and denosumab), bone-forming agents (i.e. peptides from the parathyroid hormone family) and one agent with a dual mechanism of action (i.e. strontium ranelate). All these medications combine antifracture efficacy with a reasonable benefit/risk profile. However, the choice of a particular chemical entity, in one individual patient is based on the knowledge and expertise of the physician. Prioritization of drugs should be based on the individual profile of the patient, the severity of osteoporosis and the specific contraindications, warnings and precautions of use of the various available medications. (C) 2014 Elsevier Ltd. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据